(1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethyl(4,4,4',4',6',9'-2H6)spiro[oxolane-2,14'-tetracyclo[8.7.0.02,7.011,15]heptadecan]-6'-ene-5,5'-dione

• ChemBase ID: 177855
• Molecular Formular: C24H32O4S
• Molecular Mass: 416.57348
• Monoisotopic Mass: 416.2021305
• SMILES: C1C(=O)C=C2[C@](C1)([C@@H]1[C@@H]([C@@H](C2)SC(=O)C)[C@H]2[C@](CC1)([C@]1(CC2)OC(=O)CC1)C)C
• Canonical SMILES: CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]2[C@@H]1[C@@H]1CC[C@]3([C@]1(CC2)C)CCC(=O)O3)C
• InChI: InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
• InChIKey: LXMSZDCAJNLERA-ZHYRCANASA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethyl(4,4,4',4',6',9'-^2H₆)spiro[oxolane-2,14'-tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan]-6'-ene-5,5'-dione
• IUPAC Traditional name: (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethyl(4,4,4',4',6',9'-^2H₆)spiro[oxolane-2,14'-tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan]-6'-ene-5,5'-dione
• Synonyms: (7α,7α)-7-Acetylthyo-17-hydroxy-3-oxopregn-4-one-21-carboxylic Acid γ-Lactone-d6; 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone-d6; SC-9420-d6; Spironolactone-d6 (Major)

Database IDs

• PubChem SID: 164233765
• PubChem CID: 71752233

CALCULATED PROPERTIES

• Acid pKa: 18.006086
• H Acceptors: 3
• H Donor: 0
• LogD (pH = 5.5): 3.6367545
• LogD (pH = 7.4): 3.6367545
• Log P: 3.6367545
• Molar Refractivity: 113.5043 cm^3
• Polarizability: 45.065933 Å^3
• Polar Surface Area: 60.44 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: Chloroform; Methanol
• Apperance: Off-White Solid
• Melting Point: 137-139°C

Safety Information

• Storage Condition: -20°C Freezer, Under Inert Atmosphere

DETAILS

Toronto Research Chemicals - S683002

It is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics, used primarily to treat ascites in patients with liver disease, low-renin hypertension, hypokalemia

REFERENCES

• Sutter, J.L., et al.: Anal. Profiles Drug Subs., 4, 431 (1975)